RxSight, Inc. (RXST)

RxSight's stock price has declined significantly over the past six months. As of April 21, 2026, the share price was $7.09, a 50.49% decrease from the previous year. In Q1 2026, revenue decreased by 18.5% due to lower LDD sales. Despite beating revenue estimates and reporting a narrower loss per share, the stock fell in aftermarket trading. Analysts have a consensus "Reduce" rating with an average twelve-month price objective of $9.7778. Operating expenses are expected to be at the high end of the previously guided range due to investments in its global commercial organization.

RxSight has indicated that seasonality may cause fluctuations in its operating results and financial metrics. Q1 2026 LAL unit volumes were consistent with typical first-quarter seasonality. Historical data suggests that RxSight's stock has historically risen by an average of 33.1% over a 52-week period, with a 50% accuracy rate.

RxSight, Inc. is a medical technology company specializing in ophthalmic devices, specifically the Light Adjustable Lens (LAL) system. The LAL system includes an intraocular lens adjustable post-surgery with UV light and the Light Delivery Device (LDD). This technology allows for customized vision correction after cataract surgery.

RxSight is headquartered in Aliso Viejo, California, and primarily serves the U.S. market. The company has obtained CE marking in Europe and regulatory approval in New Zealand. RxSight is building a network of implantation sites throughout North America and preparing for broader global expansion.

RxSight presented clinical data at the ASCRS annual meeting, showcasing the versatility of its adjustable lens technology, which generally contributes positively to its reputation. The company also announced a milestone of 300,000 Light Adjustable Lens implants. However, the decline in stock price and a "Reduce" consensus rating from brokerages could indirectly reflect on investor sentiment.

RxSight has a mixed ownership structure including institutional, retail, and individual investors. Institutional owners hold a significant portion of shares, with major holders including BlackRock, Inc. and Vanguard Group Inc. Hedge funds own approximately 5.3% of shares. Insiders own shares worth approximately $23 million, with CEO Ronald Kurtz owning 2.0% of the company's shares. The general public holds an 11% stake.